Cohort 1 for Healthy Subjects

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Altasciences Clinical Los Angeles, Inc., Cypress, CAHealthy SubjectsCD388 Injection - CombinationProduct
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial tests if CD388 Injection is safe and tolerated when given as a single dose in healthy Japanese adults.

Treatment Effectiveness

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: At inpatient visits on Days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on Day 30 (±3 days), Day 45 (±3 days), Day 60 (±5 days), Day 90 (±7 days), and either Day 120 (±14 days) (Cohort 1 only) or Day 165 (±14 days) (Cohorts 2 and 3 only)

Day 165
Apparent Clearance (CL/F) Following CD388 Injection Administration
Apparent Volume of Distribution (VZ/F) Following CD388 Injection Administration
Area Under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC[0-∞]) Following CD388 Injection Administration
Area Under the Plasma Concentration-Time Curve from Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following CD388 Injection Administration
Maximum Plasma Concentration (Cmax) Following CD388 Injection Administration
Terminal Elimination Half-life (t½) Following CD388 Injection Administration
Time to Maximum Plasma Concentration (Tmax) Following CD388 Injection Administration
Day 165
Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs) after a Single Dose of CD388

Trial Safety

Trial Design

3 Treatment Groups

Cohort 1
1 of 3
Cohort 2
1 of 3
Cohort 3
1 of 3

Experimental Treatment

27 Total Participants · 3 Treatment Groups

Primary Treatment: Cohort 1 · Has Placebo Group · Phase 1

Cohort 1Experimental Group · 2 Interventions: CD388 Injection, Saline placebo · Intervention Types: CombinationProduct, Drug
Cohort 2Experimental Group · 2 Interventions: CD388 Injection, Saline placebo · Intervention Types: CombinationProduct, Drug
Cohort 3Experimental Group · 2 Interventions: CD388 Injection, Saline placebo · Intervention Types: CombinationProduct, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Saline placebo
2005
Completed Phase 4
~22090

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: at inpatient visits on days 1, 2, 3, 4, 5, 6, 7, 9, 11, and 14; and at outpatient visits on day 30 (±3 days), day 45 (±3 days), day 60 (±5 days), day 90 (±7 days), and either day 120 (±14 days) (cohort 1 only) or day 165 (±14 days) (cohorts 2 and 3 only)

Who is running the clinical trial?

Janssen PharmaceuticalsIndustry Sponsor
72 Previous Clinical Trials
18,962 Total Patients Enrolled
Cidara Therapeutics Inc.Lead Sponsor
10 Previous Clinical Trials
2,327 Total Patients Enrolled
Youngjun Kim, MDPrincipal InvestigatorAltasciences Clinical Los Angeles, Inc.
Ozlem Equils, MDStudy DirectorCidara Therapeutics Inc.
2 Previous Clinical Trials
245 Total Patients Enrolled

Eligibility Criteria

Age 18 - 65 · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Women cannot donate their eggs for assisted reproduction during the study and for at least 7 months after taking the study drug.

Frequently Asked Questions

Who meets the qualifications to participate in this research?

"This study demands 18 participants, aged between the ages of eighteen and sixty-five with healthy subjective states (hs). Additionally, they must be Japanese descending on both their maternal and paternal sides as reported by themselves. Willingness to provide written consent is also a necessity for those looking to join this clinical trial. Furthermore, male or female volunteers have to fulfill various requirements such as using contraception if capable of bearing children; being surgically sterile or past menopause in case incapable; having negative serum/urine pregnancy tests at screening & day -1 before first dose respectively; abstaining from donating eggs during the course & at least 7 months" - Anonymous Online Contributor

Unverified Answer

What is the size of the cohort involved in this research?

"Affirmative, the information accessible on clinicaltrials.gov indicates that this medical experiment is actively enrolling volunteers. First posted on October 18th 2022 and updated as recently as November 9th 2022, the trial seeks to recruit a total of eighteen patients from one site." - Anonymous Online Contributor

Unverified Answer

To what degree can Cohort 1 be potentially hazardous to those involved?

"Cohort 1's safety score was assessed at a value of one due to the limited research data available concerning its efficacy and security." - Anonymous Online Contributor

Unverified Answer

Does this clinical trial accept applicants who are over 50 years of age?

"As per the requirements of this clinical trial, only those aged 18 or above and 65 or under are welcome to participate." - Anonymous Online Contributor

Unverified Answer

Are there any vacancies for participants in this research endeavor?

"Affirmative. The public data found on clinicaltrials.gov confirms that this investigation, which was initially published on October 18th 2022, is actively recruiting participants. They are aiming to find 18 volunteers from one medical site in total." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.